Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1436 | Exercise Wiki | 0.41 |
| drug3192 | Questionnaire Wiki | 0.12 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
| D018352 | Coronavirus Infections NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this registry study is to investigate the effectiveness and safety of the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) in the treatment of COVID-19 patients.
Description: Overall Survival after Seraph 100 therapy session
Measure: Survival Time: 30 daysDescription: Time spend in the ICU after Seraph 100 therapy session
Measure: Length of ICU stay Time: 30 daysDescription: Time spend in the hospital after Seraph 100 therapy session
Measure: Length of Hospital stay Time: 30 daysDescription: Time spend on ventilator after Seraph 100 therapy session
Measure: Length of ventilator therapy Time: 30 daysDescription: Report of any Seraph 100 therapy related adverse events
Measure: Adverse events Time: 30 daysSafety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the treatment of patients with COVID-19
Description: Change in organ failure as assessed by a modified Sequential Organ Failure Assessment score (range, 0-24 hours, with higher scores indicating more dysfunction) from baseline to 48 hours
Measure: Change in Organ failure Time: upto 48 hoursDescription: Change in organ failure as assessed by a modified Sequential Organ Failure Assessment score (range 0 - 24 hours, with higher scores indicating more dysfunction
Measure: Change in Organ Failure Time: During ICU stay at 12hours, 24hours, 36hours, 96hours after treatmentDescription: All-cause mortality
Measure: All-cause mortality Time: up to 28 daysDescription: Reduction of viral load
Measure: Change in Viral load Time: up to 5 hoursDescription: Organ dysfunction-free days
Measure: Organ dysfunction-free days Time: up to 28 daysDescription: Reduction of Intensive Care Unit (ICU) complications
Measure: ICU complications Time: Daily during ICU stay up to 28 daysDescription: Ventilator-free days (VFDs
Measure: Ventilator-free days (VFDs Time: Daily ICU stay up to 28 daysDescription: Length of stay (LOS) at ICU and hospital ward
Measure: Length of stay (LOS) at ICU Time: Daily up to 28 daysDescription: Change of prognosis factors (D-Dimere, Troponin T, Ferritin, NTpro-BNP, LDH, IL6, sIL2
Measure: Prognosis Factors Time: up to 48 hoursAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports